I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Cost-effectiveness of pembrolizumab for previously treated ..:
Grant McCarthy
;
Kate Young
;
Matthew Madin-Warburton
...
doi:10.6084/m9.figshare.25117347.v1. , 2024
Link:
https://doi.org/10.6084/m9.figshare.25117347.v1
RT Journal T1
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK
UL https://suche.suub.uni-bremen.de/peid=base-ftdeakinunifig:oai:figshare.com:article_25117347&Exemplar=1&LAN=DE A1 Grant McCarthy A1 Kate Young A1 Matthew Madin-Warburton A1 Tyler Mantaian A1 Elizabeth Brook A1 Kaylie Metcalfe A1 Jan Mikelson A1 Ruifeng Xu A1 Carl Seyla-Hammer A1 Raquel Aguiar-Ibáñez A1 Mayur Amonkar YR 2024 K1 Biochemistry K1 Medicine K1 Pharmacology K1 Cancer K1 Science Policy K1 Biological Sciences not elsewhere classified K1 Chemical Sciences not elsewhere classified K1 Microsatellite instability K1 mismatch repair deficient K1 economic analysis K1 cost-effectiveness K1 pembrolizumab K1 multi-tumour K1 histology-independent K1 D61 K1 D6 K1 D K1 H51 K1 H5 K1 H JF doi:10.6084/m9.figshare.25117347.v1 LK http://dx.doi.org/https://doi.org/10.6084/m9.figshare.25117347.v1 DO https://doi.org/10.6084/m9.figshare.25117347.v1 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)